151 related articles for article (PubMed ID: 35912498)
1. A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials.
Nosrati M; Nikfar S; Hasanzad M
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1061-1070. PubMed ID: 35912498
[TBL] [Abstract][Full Text] [Related]
2. Conducting economic evaluation based on basket clinical trial in the area of precision medicine.
Nosrati M; Nikfar S
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):169-171. PubMed ID: 33356657
[No Abstract] [Full Text] [Related]
3. Bayesian basket trial design with exchangeability monitoring.
Hobbs BP; Landin R
Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
[TBL] [Abstract][Full Text] [Related]
4. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of precision medicine: a scoping review.
Kasztura M; Richard A; Bempong NE; Loncar D; Flahault A
Int J Public Health; 2019 Dec; 64(9):1261-1271. PubMed ID: 31650223
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
Langer A
BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluation of Hospital and Community Pharmacy Services.
Gammie T; Vogler S; Babar ZU
Ann Pharmacother; 2017 Jan; 51(1):54-65. PubMed ID: 27586430
[TBL] [Abstract][Full Text] [Related]
8. Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review.
Wright SJ; Newman WG; Payne K
Pharmacoeconomics; 2019 Aug; 37(8):1011-1027. PubMed ID: 31087278
[TBL] [Abstract][Full Text] [Related]
9. An overview of precision oncology basket and umbrella trials for clinicians.
Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ
CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692
[TBL] [Abstract][Full Text] [Related]
10. Bone graft substitutes for the treatment of traumatic fractures of the extremities.
Hagen A; Gorenoi V; Schönermark MP
GMS Health Technol Assess; 2012; 8():Doc04. PubMed ID: 22984371
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
12. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
13. What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?
van Dongen JM; El Alili M; Varga AN; Guevara Morel AE; Jornada Ben A; Khorrami M; van Tulder MW; Bosmans JE
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):27-37. PubMed ID: 31731882
[No Abstract] [Full Text] [Related]
14. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.
Doble B; Tan M; Harris A; Lorgelly P
Expert Rev Mol Diagn; 2015 Feb; 15(2):235-54. PubMed ID: 25142227
[TBL] [Abstract][Full Text] [Related]
15. The economic case for precision medicine.
Gavan SP; Thompson AJ; Payne K
Expert Rev Precis Med Drug Dev; 2018; 3(1):1-9. PubMed ID: 29682615
[No Abstract] [Full Text] [Related]
16. Definitions and statistical properties of master protocols for personalized medicine in oncology.
Renfro LA; Mandrekar SJ
J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine and economic evaluation in oncology: all theory and no practice?
Garattini L; Curto A; Freemantle N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
[TBL] [Abstract][Full Text] [Related]
18. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.
Phillips KA; Douglas MP; Trosman JR; Marshall DA
Value Health; 2017 Jan; 20(1):47-53. PubMed ID: 28212968
[TBL] [Abstract][Full Text] [Related]
19. Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'.
Leonetti A; Boyd L; Giuliani J; Giovannetti E; Garajová I
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1033-1036. PubMed ID: 31633383
[No Abstract] [Full Text] [Related]
20. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
